Related Experiment Video
Updated: Jul 1, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across
Ilias Houda1, Chris Dickhoff2, Carin A Uyl-de Groot3
1Department of Pulmonary Medicine, Amsterdam UMC, Location VU Medical Center, Cancer Center Amsterdam, de Boelelaan 1117, 1081HV, Amsterdam, the Netherlands.
Abstract:
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) compares and contrasts approaches taken by the European Medicines Agency (EMA) for drug approval to that taken by the United States Food and Drug Administration (FDA), and (iii) evaluates the differences in access to emerging treatments from an availability perspective across European countries.
Insights
Novel immunotherapies and targeted treatments are transforming early-stage non-small cell lung cancer (NSCLC) care. However, varying European regulations and reimbursement may create unequal patient access to these advancements.
Area of Science:
- Oncology
- Clinical Trials
- Health Economics
Background:
- The treatment landscape for resectable early-stage non-small cell lung cancer (NSCLC) is evolving rapidly.
- Recent randomized trials show promise for neoadjuvant/adjuvant immunotherapy and adjuvant targeted therapy.
Purpose of the Study:
- To analyze clinical studies impacting resectable early-stage NSCLC treatment.
- To compare EMA and FDA drug approval processes.
- To evaluate cross-European access disparities for new lung cancer therapies.
Main Methods:
- Review of randomized clinical trials and regulatory approvals.
- Comparative analysis of European Medicines Agency (EMA) and US Food and Drug Administration (FDA) drug authorizations.
- Assessment of treatment availability and access variations across European nations.
Main Results:
- Emerging immunotherapies and targeted therapies are reshaping treatment paradigms.
- Regulatory approvals are increasing, with further expected.
- Significant variations in cost-effectiveness and reimbursement criteria exist across Europe, potentially impacting patient access.
Conclusions:
- New treatment options offer significant potential for early-stage NSCLC.
- Regulatory harmonization and equitable reimbursement are crucial for consistent patient care across Europe.
- Addressing access inequalities is essential to ensure all European patients benefit from advancements in lung cancer treatment.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...